Neurocrine Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| N1BI34.SA | SUVEN.BO | 0ND5.IL | ALKS | 0QFP.IL | SUPN | |
|---|---|---|---|---|---|---|
| Market cap | 93.02B | 63.96B | 55.21B | 7.71B | 4.46T | 1.64B |
| P/E (TTM) | 26.1 | — | 22.4 | — | 18.8 | — |
| Forward P/E | — | 23.5 | 25.0 | 25.4 | — | 6.3 |
| Price/book | 4.8 | 21.8 | 2.6 | 4.1 | 2.1 | -55.5 |
| Dividend yield | — | — | 1.58% | — | 7.74% | — |
| 1-year change | +10.78% | +30.58% | +20.02% | +44.85% | 0.00% | −11.32% |
| Today | −0.02% | −0.14% | +0.18% | +0.44% | +156.25% | +0.21% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All N1BI34.SA news ›Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Todd Tushla - Vice President of Investor RelationsKyle Gano - President, CEO & DirectorMatthew Abernethy - Chief Financial OfficerEric Benevich - Chief…
Neurocrine Biosciences Presents 2-Year Results from Cahtalyst Pediatric and Cahtalyst Adult Studies of Crinecerfont
Published on 10/16/2026 at 01:50 pm EDT Neurocrine Biosciences, Inc. announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve…
Neurocrine Biosciences' Vykat XR Sales Likely to Remain 'Flattish' Near Term, RBC Says
Neurocrine Biosciences' sales of its Vykat extended-release tablets for hyperphagia are likely to remain flattish in the near term, but could return to some growth over time, RBC Capital Markets... Neurocrine Biosciences' Vykat XR Sales…
Neurocrine Biosciences, Inc.: Relative Strength Chart - Stock Nasdaq
Compare Neurocrine Biosciences, Inc. with the company of your choice via a Relative Strength chart. Real-time NBIX price, Nasdaq stock exchange Relative Strength Chart Neurocrine Biosciences, Inc. All financial news and data tailored to…
Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
Oct 30, 2026, 08:30 ET The curriculum currently includes two modules, through which healthcare providers can explore topics on disease pathophysiology, diagnostic approaches and the role of glucocorticoids and crinecerfont in the…
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with INGREZZA®(valbenazine) capsules The…
Where Will Neurocrine Biosciences Be in 5 Years?
By 2031, I expect Neurocrine to be a substantially larger pharmaceutical company, potentially generating more than $6 billion in annual revenue. Whether its stock follows that growth, however, will depend on the success of its newer drugs…
Neurocrine Biosciences (NBIX) Projected to Announce Quarterly Earnings on Monday
Posted by Defense World Staff on Oct 26th, 2026 Shares of NBIX opened at $142.70 on Monday. Neurocrine Biosciences has a 12-month low of $122.14 and a 12-month high of $186.12. The business’s fifty day moving average is $147.49 and its 200…
Neurocrine Biosciences starts 135‑patient Alzheimer's cognition trial
The placebo-controlled study tests two doses of NBI-'567 over 12 weeks, with primary completion estimated for May 2028. A trial targeting 135 patients with Alzheimer's cognitive impairment has begun, as Neurocrine Biosciences, Inc.…
Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment
Neurocrine Biosciences has launched a Phase 2 clinical trial for NBI-1117567 (NBI-'567), an oral drug targeting muscarinic receptors to improve cognition in adults with mild to moderate Alzheimer's disease. The study will test the drug's…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com5
- stocktitan.net3
- defenseworld.net2
- seekingalpha.com2
- themarketsdaily.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.